207 related articles for article (PubMed ID: 26174566)
1. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).
Tanaka M; Roberts JM; Qi J; Bradner JE
Pharm Pat Anal; 2015; 4(4):261-84. PubMed ID: 26174566
[TBL] [Abstract][Full Text] [Related]
2. Deal watch: MSD buys in to emerging epigenetic cancer target.
Cully M
Nat Rev Drug Discov; 2016 Mar; 15(3):153. PubMed ID: 26931086
[No Abstract] [Full Text] [Related]
3. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
4. Development and classes of epigenetic drugs for cancer.
Dhanak D; Jackson P
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):58-69. PubMed ID: 25016182
[TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
7. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
8. Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
Anaya-Ruiz M; Bandala C; Landeta G; Martínez-Morales P; Zumaquero-Rios JL; Sarracent-Pérez J; Pérez-Santos M
Recent Pat Anticancer Drug Discov; 2019; 14(1):85-94. PubMed ID: 30381087
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic drugs against cancer: an evolving landscape.
Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
[TBL] [Abstract][Full Text] [Related]
10. Emerging molecular therapies of advanced thyroid cancer.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Mol Aspects Med; 2010 Apr; 31(2):215-26. PubMed ID: 20176050
[TBL] [Abstract][Full Text] [Related]
11. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
12. BET Inhibitors as Anticancer Agents: A Patent Review.
Ali I; Choi G; Lee K
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetic regulators for cancer therapy.
Wee S; Dhanak D; Li H; Armstrong SA; Copeland RA; Sims R; Baylin SB; Liu XS; Schweizer L
Ann N Y Acad Sci; 2014 Feb; 1309():30-6. PubMed ID: 24571255
[TBL] [Abstract][Full Text] [Related]
14. Delivery of epidrugs.
el Bahhaj F; Dekker FJ; Martinet N; Bertrand P
Drug Discov Today; 2014 Sep; 19(9):1337-52. PubMed ID: 24680930
[TBL] [Abstract][Full Text] [Related]
15. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
Marzaro G; Guiotto A; Chilin A
Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
[TBL] [Abstract][Full Text] [Related]
16. Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers.
Unoki M
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):116-30. PubMed ID: 21110828
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic opportunities and challenges in cancer.
Best JD; Carey N
Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
Poulsen SA
Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.
Lu R; Wang GG
Front Oncol; 2017; 7():241. PubMed ID: 29075615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
